Ceftazidime therapy of serious bacterial infections
Authors:
- L J EronLEL J Eron
- R I GoldenbergRGR I Goldenberg
- C H ParkCPC H Park
- D M PoretzDPD M Poretz
- 1 February 1983
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 23 (2) , 236-241
Abstract
Ceftazidime, a new broad-spectrum cephalosporin, was administered to 30 patients with serious bacterial infections in a randomized dosing trial with daily doses of 1.5 or 3 g. Both regimens were equally efficacious, with satisfactory clinical responses in 28 instances (93%) and microbiological eradication of 79% of initial bacterial isolates. The development of resistance to ceftazidime during therapy was observed in three cases (Enterobacter agglomerans, Enterobacter cloacae, and Pseudomonas aeruginosa) and superinfection by a resistant Enterobacter agglomerans strain occurred in one case. Adverse reactions of clinical significance included one case each of leukopenia, azotemia, diarrhea (Clostridium difficile toxin positive), and rash.Keywords
This publication has 5 references indexed in Scilit:
- CEFTAZIDIME—A NEW EXTENDED-SPECTRUM CEPHALOSPORINThe Lancet, 1982
- Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1982
- Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapyAntimicrobial Agents and Chemotherapy, 1981
- GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activityAntimicrobial Agents and Chemotherapy, 1980
- Simplified, Accurate Method for Antibiotic Assay of Clinical SpecimensApplied Microbiology, 1966